CN Patent

CN111265499B — 一种洛匹那韦吸入气雾剂及其制备方法

Assigned to Jiangsu Ailikang Pharmaceutical Technology Co ltd · Expires 2022-11-15 · 4y expired

What this patent protects

本发明属于医药技术领域，公开了一种洛匹那韦吸入气雾剂及其制备方法。所述的洛匹那韦吸入气雾剂由活性成分洛匹那韦与一定比例的抛射剂、助溶剂、表面活性剂等组成，所述的气雾吸入剂经口腔给药，直接作用肺部，实现靶向给药。本发明的吸入制剂可靶向病灶，剂量准确，起效快，可以快速改善肺部感染情况，有利于改善感染者的适应力，同时避免经过胃肠道吸收，减小胃肠道副作用。

USPTO Abstract

本发明属于医药技术领域，公开了一种洛匹那韦吸入气雾剂及其制备方法。所述的洛匹那韦吸入气雾剂由活性成分洛匹那韦与一定比例的抛射剂、助溶剂、表面活性剂等组成，所述的气雾吸入剂经口腔给药，直接作用肺部，实现靶向给药。本发明的吸入制剂可靶向病灶，剂量准确，起效快，可以快速改善肺部感染情况，有利于改善感染者的适应力，同时避免经过胃肠道吸收，减小胃肠道副作用。

Drugs covered by this patent

Patent Metadata

Patent number
CN111265499B
Jurisdiction
CN
Classification
—
Expires
2022-11-15
Drug substance claim
No
Drug product claim
No
Assignee
Jiangsu Ailikang Pharmaceutical Technology Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.